

David J Nutt

List of Publications by Citations

Source: <https://exaly.com/author-pdf/3010967/david-j-nutt-publications-by-citations.pdf>

Version: 2024-04-24

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

551
papers

30,842
citations

91
h-index

156
g-index

615
ext. papers

36,802
ext. citations

6.4
avg, IF

7.49
L-index

#	Paper	IF	Citations
551	Translocator protein (18kDa): new nomenclature for the peripheral-type benzodiazepine receptor based on its structure and molecular function. <i>Trends in Pharmacological Sciences</i> , 2006 , 27, 402-9	13.2	1097
550	Drug harms in the UK: a multicriteria decision analysis. <i>Lancet, The</i> , 2010 , 376, 1558-65	40	908
549	Development of a rational scale to assess the harm of drugs of potential misuse. <i>Lancet, The</i> , 2007 , 369, 1047-53	40	779
548	Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. <i>Lancet Psychiatry, the</i> , 2016 , 3, 619-27	23.3	568
547	Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012 , 109, 2138-43	11.5	555
546	Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology. <i>Journal of Psychopharmacology</i> , 2005 , 19, 567-96	4.6	449
545	The entropic brain: a theory of conscious states informed by neuroimaging research with psychedelic drugs. <i>Frontiers in Human Neuroscience</i> , 2014 , 8, 20	3.3	409
544	Neural correlates of the LSD experience revealed by multimodal neuroimaging. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016 , 113, 4853-8	11.5	401
543	The dopamine theory of addiction: 40 years of highs and lows. <i>Nature Reviews Neuroscience</i> , 2015 , 16, 305-12	13.5	392
542	Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: a revision of the 2005 guidelines from the British Association for Psychopharmacology. <i>Journal of Psychopharmacology</i> , 2014 , 28, 403-39	4.6	387
541	Evidence-based guidelines for treating depressive disorders with antidepressants: A revision of the 2008 British Association for Psychopharmacology guidelines. <i>Journal of Psychopharmacology</i> , 2015 , 29, 459-525	4.6	381
540	British Association for Psychopharmacology consensus statement on evidence-based treatment of insomnia, parasomnias and circadian rhythm disorders. <i>Journal of Psychopharmacology</i> , 2010 , 24, 1577-601	4.6	365
539	Role of GABA in anxiety and depression. <i>Depression and Anxiety</i> , 2007 , 24, 495-517	8.4	335
538	Decreased brain GABA(A)-benzodiazepine receptor binding in panic disorder: preliminary results from a quantitative PET study. <i>Archives of General Psychiatry</i> , 1998 , 55, 715-20		314
537	Amphetamine, past and present--a pharmacological and clinical perspective. <i>Journal of Psychopharmacology</i> , 2013 , 27, 479-96	4.6	300
536	Unusual interactions of benzodiazepine receptor antagonists. <i>Nature</i> , 1982 , 295, 436-8	50.4	276
535	Homological scaffolds of brain functional networks. <i>Journal of the Royal Society Interface</i> , 2014 , 11, 20140873	10.73	269

534	GABA system dysfunction in autism and related disorders: from synapse to symptoms. <i>Neuroscience and Biobehavioral Reviews</i> , 2012 , 36, 2044-55	9	268
533	Psilocybin with psychological support for treatment-resistant depression: six-month follow-up. <i>Psychopharmacology</i> , 2018 , 235, 399-408	4.7	266
532	Broadband cortical desynchronization underlies the human psychedelic state. <i>Journal of Neuroscience</i> , 2013 , 33, 15171-83	6.6	258
531	Serotonin and brain function: a tale of two receptors. <i>Journal of Psychopharmacology</i> , 2017 , 31, 1091-1120	4.6	254
530	The other face of depression, reduced positive affect: the role of catecholamines in causation and cure. <i>Journal of Psychopharmacology</i> , 2007 , 21, 461-71	4.6	253
529	The anxiogenic action of benzodiazepine antagonists. <i>Neuropharmacology</i> , 1982 , 21, 1033-7	5.5	246
528	Factors influencing success of clinical genome sequencing across a broad spectrum of disorders. <i>Nature Genetics</i> , 2015 , 47, 717-726	36.3	244
527	New insights into the role of the GABA(A)-benzodiazepine receptor in psychiatric disorder. <i>British Journal of Psychiatry</i> , 2001 , 179, 390-6	5.4	244
526	Quality of Acute Psychedelic Experience Predicts Therapeutic Efficacy of Psilocybin for Treatment-Resistant Depression. <i>Frontiers in Pharmacology</i> , 2017 , 8, 974	5.6	242
525	Increased Global Functional Connectivity Correlates with LSD-Induced Ego Dissolution. <i>Current Biology</i> , 2016 , 26, 1043-50	6.3	237
524	Estimating the harms of nicotine-containing products using the MCDA approach. <i>European Addiction Research</i> , 2014 , 20, 218-25	4.6	235
523	'Seeing through a glass darkly': casting light on imidazoline 'I' sites. <i>Trends in Pharmacological Sciences</i> , 1998 , 19, 381-90	13.2	232
522	Flumazenil provocation of panic attacks. Evidence for altered benzodiazepine receptor sensitivity in panic disorder. <i>Archives of General Psychiatry</i> , 1990 , 47, 917-25		222
521	Tryptophan depletion and its implications for psychiatry. <i>British Journal of Psychiatry</i> , 2001 , 178, 399-405	5.4	213
520	Enhanced repertoire of brain dynamical states during the psychedelic experience. <i>Human Brain Mapping</i> , 2014 , 35, 5442-56	5.9	211
519	Evidence-based guidelines for management of attention-deficit/hyperactivity disorder in adolescents in transition to adult services and in adults: recommendations from the British Association for Psychopharmacology. <i>Journal of Psychopharmacology</i> , 2007 , 21, 10-41	4.6	205
518	BAP updated guidelines: evidence-based guidelines for the pharmacological management of substance abuse, harmful use, addiction and comorbidity: recommendations from BAP. <i>Journal of Psychopharmacology</i> , 2012 , 26, 899-952	4.6	204
517	A web-based survey on mephedrone. <i>Drug and Alcohol Dependence</i> , 2011 , 118, 19-22	4.9	200

516	Psilocybin for treatment-resistant depression: fMRI-measured brain mechanisms. <i>Scientific Reports</i> , 2017 , 7, 13187	4.9	192
515	Evidence-based guidelines for the pharmacological management of attention deficit hyperactivity disorder: update on recommendations from the British Association for Psychopharmacology. <i>Journal of Psychopharmacology</i> , 2014 , 28, 179-203	4.6	191
514	Resolution of sleepiness and fatigue in major depressive disorder: A comparison of bupropion and the selective serotonin reuptake inhibitors. <i>Biological Psychiatry</i> , 2006 , 60, 1350-5	7.9	183
513	Effects of Schedule I drug laws on neuroscience research and treatment innovation. <i>Nature Reviews Neuroscience</i> , 2013 , 14, 577-85	13.5	178
512	LSD-induced entropic brain activity predicts subsequent personality change. <i>Human Brain Mapping</i> , 2016 , 37, 3203-13	5.9	163
511	The neuropharmacology of serotonin and noradrenaline in depression. <i>International Clinical Psychopharmacology</i> , 2002 , 17 Suppl 1, S1-12	2.2	159
510	Striatal dopamine D ₁ /D ₅ receptor binding in pathological gambling is correlated with mood-related impulsivity. <i>NeuroImage</i> , 2012 , 63, 40-6	7.9	156
509	The paradoxical psychological effects of lysergic acid diethylamide (LSD). <i>Psychological Medicine</i> , 2016 , 46, 1379-90	6.9	156
508	Defining substance use disorders: do we really need more than heavy use?. <i>Alcohol and Alcoholism</i> , 2013 , 48, 633-40	3.5	155
507	Patients' Accounts of Increased Connectedness and Acceptance After Psilocybin for Treatment-Resistant Depression. <i>Journal of Humanistic Psychology</i> , 2017 , 57, 520-564	0.9	154
506	Trial of Psilocybin versus Escitalopram for Depression. <i>New England Journal of Medicine</i> , 2021 , 384, 1402-1411	5.9	152
505	Functional connectivity measures after psilocybin inform a novel hypothesis of early psychosis. <i>Schizophrenia Bulletin</i> , 2013 , 39, 1343-51	1.3	148
504	Serotonin 5-HT _{1A} receptor binding in people with panic disorder: positron emission tomography study. <i>British Journal of Psychiatry</i> , 2008 , 193, 229-34	5.4	147
503	Human taste thresholds are modulated by serotonin and noradrenaline. <i>Journal of Neuroscience</i> , 2006 , 26, 12664-71	6.6	146
502	Biological markers for anxiety disorders, OCD and PTSD: A consensus statement. Part II: Neurochemistry, neurophysiology and neurocognition. <i>World Journal of Biological Psychiatry</i> , 2017 , 18, 162-214	3.8	143
501	Panic attacks. A neurochemical overview of models and mechanisms. <i>British Journal of Psychiatry</i> , 1992 , 160, 165-78	5.4	134
500	Overview of diagnosis and drug treatments of anxiety disorders. <i>CNS Spectrums</i> , 2005 , 10, 49-56	1.8	133
499	Changes in regional cerebral blood flow elicited by craving memories in abstinent opiate-dependent subjects. <i>American Journal of Psychiatry</i> , 2001 , 158, 1680-6	11.9	133

498	Benzodiazepines: risks and benefits. A reconsideration. <i>Journal of Psychopharmacology</i> , 2013 , 27, 967-714.6	130
497	Altered central alpha 2-adrenoceptor sensitivity in panic disorder. <i>Archives of General Psychiatry</i> , 1989 , 46, 165-9	129
496	Ego-Dissolution and Psychedelics: Validation of the Ego-Dissolution Inventory (EDI). <i>Frontiers in Human Neuroscience</i> , 2016 , 10, 269	3.3 129
495	Neural correlates of change in major depressive disorder anhedonia following open-label ketamine. <i>Journal of Psychopharmacology</i> , 2015 , 29, 596-607	4.6 128
494	The effects of psilocybin and MDMA on between-network resting state functional connectivity in healthy volunteers. <i>Frontiers in Human Neuroscience</i> , 2014 , 8, 204	3.3 128
493	LSD enhances suggestibility in healthy volunteers. <i>Psychopharmacology</i> , 2015 , 232, 785-94	4.7 127
492	Evidence-based guidelines for the pharmacological management of substance misuse, addiction and comorbidity: recommendations from the British Association for Psychopharmacology. <i>Journal of Psychopharmacology</i> , 2004 , 18, 293-335	4.6 127
491	Invited review: the evolution of antidepressant mechanisms. <i>Fundamental and Clinical Pharmacology</i> , 2004 , 18, 1-21	3.1 127
490	Antidepressant-induced jitteriness/anxiety syndrome: systematic review. <i>British Journal of Psychiatry</i> , 2009 , 194, 483-90	5.4 123
489	Finding the self by losing the self: Neural correlates of ego-dissolution under psilocybin. <i>Human Brain Mapping</i> , 2015 , 36, 3137-53	5.9 122
488	Implications for psychedelic-assisted psychotherapy: functional magnetic resonance imaging study with psilocybin. <i>British Journal of Psychiatry</i> , 2012 , 200, 238-44	5.4 122
487	Stratified medicine for mental disorders. <i>European Neuropsychopharmacology</i> , 2014 , 24, 5-50	1.2 121
486	Noradrenaline and attention lapses. <i>Nature</i> , 1996 , 380, 291	50.4 120
485	Measuring endogenous 5-HT release by emission tomography: promises and pitfalls. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2010 , 30, 1682-706	7.3 115
484	beta-carboline binding to imidazoline receptors. <i>Drug and Alcohol Dependence</i> , 2001 , 64, 203-8	4.9 112
483	Functional studies of specific imidazoline-2 receptor ligands. <i>Annals of the New York Academy of Sciences</i> , 1995 , 763, 125-39	6.5 112
482	5-HT radioligands for human brain imaging with PET and SPECT. <i>Medicinal Research Reviews</i> , 2013 , 33, 54-111	14.4 111
481	Searching for perfect sleep: the continuing evolution of GABAA receptor modulators as hypnotics. <i>Journal of Psychopharmacology</i> , 2010 , 24, 1601-12	4.6 110

480	Psychiatry & the psychedelic drugs. Past, present & future. <i>Neuropharmacology</i> , 2018 , 142, 200-218	5.5	109
479	The size, burden and cost of disorders of the brain in the UK. <i>Journal of Psychopharmacology</i> , 2013 , 27, 761-70	4.6	109
478	The effects of elevated endogenous GABA levels on movement-related network oscillations. <i>NeuroImage</i> , 2013 , 66, 36-41	7.9	108
477	Acute and chronic effects of cannabinoids on effort-related decision-making and reward learning: an evaluation of the cannabis 'amotivational' hypotheses. <i>Psychopharmacology</i> , 2016 , 233, 3537-52	4.7	106
476	Predicting Responses to Psychedelics: A Prospective Study. <i>Frontiers in Pharmacology</i> , 2018 , 9, 897	5.6	104
475	Which antidepressants have demonstrated superior efficacy? A review of the evidence. <i>International Clinical Psychopharmacology</i> , 2007 , 22, 323-9	2.2	103
474	British Association for Psychopharmacology consensus statement on evidence-based treatment of insomnia, parasomnias and circadian rhythm disorders: An update. <i>Journal of Psychopharmacology</i> , 2019 , 33, 923-947	4.6	98
473	Determination of [(11)C]PBR28 binding potential in vivo: a first human TSPO blocking study. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2014 , 34, 989-94	7.3	98
472	European rating of drug harms. <i>Journal of Psychopharmacology</i> , 2015 , 29, 655-60	4.6	97
471	Blockade of alcohol's amnesic activity in humans by an alpha5 subtype benzodiazepine receptor inverse agonist. <i>Neuropharmacology</i> , 2007 , 53, 810-20	5.5	97
470	Characterization and autoradiographical localization of non-adrenoceptor idazoxan binding sites in the rat brain. <i>British Journal of Pharmacology</i> , 1992 , 106, 1019-27	8.6	97
469	The Effects of Acutely Administered 3,4-Methylenedioxymethamphetamine on Spontaneous Brain Function in Healthy Volunteers Measured with Arterial Spin Labeling and Blood Oxygen Level-Dependent Resting State Functional Connectivity. <i>Biological Psychiatry</i> , 2015 , 78, 554-62	7.9	96
468	Neural substrates of cue reactivity and craving in gambling disorder. <i>Translational Psychiatry</i> , 2017 , 7, e992	8.6	95
467	Imaging the GABA-benzodiazepine receptor subtype containing the alpha5-subunit in vivo with [11C]Ro15 4513 positron emission tomography. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2002 , 22, 878-89	7.3	95
466	Stimulants: use and abuse in the treatment of attention deficit hyperactivity disorder. <i>Current Opinion in Pharmacology</i> , 2005 , 5, 87-93	5.1	94
465	Mechanisms of Action and Persistent Neuroplasticity by Drugs of Abuse. <i>Pharmacological Reviews</i> , 2015 , 67, 872-1004	22.5	93
464	Biological markers for anxiety disorders, OCD and PTSD - a consensus statement. Part I: Neuroimaging and genetics. <i>World Journal of Biological Psychiatry</i> , 2016 , 17, 321-65	3.8	93
463	Decreased mental time travel to the past correlates with default-mode network disintegration under lysergic acid diethylamide. <i>Journal of Psychopharmacology</i> , 2016 , 30, 344-53	4.6	93

462	Acute tryptophan depletion. Part I: rationale and methodology. <i>Australian and New Zealand Journal of Psychiatry</i> , 2005 , 39, 558-64	2.6	93
461	Gene expression subtypes in patients with chronic fatigue syndrome/myalgic encephalomyelitis. <i>Journal of Infectious Diseases</i> , 2008 , 197, 1171-84	7	91
460	Behavioral and cardiovascular effects of 7.5% CO ₂ in human volunteers. <i>Depression and Anxiety</i> , 2005 , 21, 18-25	8.4	90
459	A review of the current nomenclature for psychotropic agents and an introduction to the Neuroscience-based Nomenclature. <i>European Neuropsychopharmacology</i> , 2015 , 25, 2318-25	1.2	89
458	Addiction: brain mechanisms and their treatment implications. <i>Lancet, The</i> , 1996 , 347, 31-6	4.0	89
457	Acute carbon dioxide exposure in healthy adults: evaluation of a novel means of investigating the stress response. <i>Journal of Neuroendocrinology</i> , 2004 , 16, 256-64	3.8	88
456	Gamma hydroxy butyrate abuse and dependency. <i>Journal of Psychopharmacology</i> , 2005 , 19, 195-204	4.6	86
455	Serotonin and panic. <i>British Journal of Psychiatry</i> , 1998 , 172, 465-71	5.4	86
454	Inhalation of 35% CO ₂ results in activation of the HPA axis in healthy volunteers. <i>Psychoneuroendocrinology</i> , 2002 , 27, 715-29	5	85
453	Effects of psilocybin therapy on personality structure. <i>Acta Psychiatrica Scandinavica</i> , 2018 , 138, 368-378	6.5	85
452	Is there cognitive impairment in clinically 'healthy' abstinent alcohol dependence?. <i>Alcohol and Alcoholism</i> , 2005 , 40, 498-503	3.5	84
451	LSD enhances the emotional response to music. <i>Psychopharmacology</i> , 2015 , 232, 3607-14	4.7	83
450	Blunted Endogenous Opioid Release Following an Oral Amphetamine Challenge in Pathological Gamblers. <i>Neuropsychopharmacology</i> , 2016 , 41, 1742-50	8.7	83
449	Endogenous opioid release in the human brain reward system induced by acute amphetamine administration. <i>Biological Psychiatry</i> , 2012 , 72, 371-7	7.9	82
448	Role of GABA in memory and anxiety. <i>Depression and Anxiety</i> , 1996 , 4, 100-10	8.4	82
447	The psychobiology of anxiolytic drug. Part 2: Pharmacological treatments of anxiety 2000 , 88, 213-27		81
446	Alcohol and the brain. Pharmacological insights for psychiatrists. <i>British Journal of Psychiatry</i> , 1999 , 175, 114-9	5.4	80
445	The brain GABA-benzodiazepine receptor alpha-5 subtype in autism spectrum disorder: a pilot [(11)C]Ro15-4513 positron emission tomography study. <i>Neuropharmacology</i> , 2013 , 68, 195-201	5.5	79

444	The effect of nicotine on striatal dopamine release in man: A [¹¹ C]raclopride PET study. <i>Synapse</i> , 2007 , 61, 637-45	2.4	79
443	Acute tryptophan depletion. Part II: clinical effects and implications. <i>Australian and New Zealand Journal of Psychiatry</i> , 2005 , 39, 565-74	2.6	79
442	Psychedelic Psychiatry's Brave New World. <i>Cell</i> , 2020 , 181, 24-28	56.2	77
441	Anhedonia revisited: is there a role for dopamine-targeting drugs for depression?. <i>Journal of Psychopharmacology</i> , 2013 , 27, 869-77	4.6	77
440	Generalized anxiety disorder: comorbidity, comparative biology and treatment. <i>International Journal of Neuropsychopharmacology</i> , 2002 , 5, 315-25	5.8	77
439	Vienna Declaration: a call for evidence-based drug policies. <i>Lancet, The</i> , 2010 , 376, 310-2	4.0	76
438	Innovative solutions to novel drug development in mental health. <i>Neuroscience and Biobehavioral Reviews</i> , 2013 , 37, 2438-44	9	75
437	Tryptophan depletion reverses the therapeutic effect of selective serotonin reuptake inhibitors in social anxiety disorder. <i>Biological Psychiatry</i> , 2004 , 56, 503-9	7.9	74
436	Overexcitement and disinhibition. Dynamic neurotransmitter interactions in alcohol withdrawal. <i>British Journal of Psychiatry</i> , 1990 , 157, 491-9	5.4	74
435	The hidden therapist: evidence for a central role of music in psychedelic therapy. <i>Psychopharmacology</i> , 2018 , 235, 505-519	4.7	73
434	GABAA Receptors: Subtypes, Regional Distribution, and Function. <i>Journal of Clinical Sleep Medicine</i> , 2006 , 02,	3.1	73
433	Does 5-HT restrain panic? A tryptophan depletion study in panic disorder patients recovered on paroxetine. <i>Journal of Psychopharmacology</i> , 2002 , 16, 5-14	4.6	73
432	Pharmacology of saccadic eye movements in man. 1. Effects of the benzodiazepine receptor ligands midazolam and flumazenil. <i>Psychopharmacology</i> , 1991 , 105, 361-7	4.7	73
431	Opioids and anxiety. <i>Journal of Psychopharmacology</i> , 2011 , 25, 1415-33	4.6	72
430	Characterisation and localisation of [³ H]2-(2-benzofuranyl)-2-imidazoline binding in rat brain: a selective ligand for imidazoline I2 receptors. <i>European Journal of Pharmacology</i> , 1998 , 353, 123-35	5.3	72
429	Functional connectivity analysis of the neural circuits of opiate craving: "more" rather than "different"?. <i>NeuroImage</i> , 2003 , 20, 1964-70	7.9	72
428	Amphetamine induced endogenous opioid release in the human brain detected with [¹¹ C]carfentanil PET: replication in an independent cohort. <i>International Journal of Neuropsychopharmacology</i> , 2014 , 17, 2069-74	5.8	71
427	GABAB receptors in addiction and its treatment. <i>Advances in Pharmacology</i> , 2010 , 58, 373-96	5.7	71

426	The psychobiology of anxiolytic drugs. Part 1: Basic neurobiology 2000 , 88, 197-212		70
425	Novel selective compounds for the investigation of imidazoline receptors. <i>Annals of the New York Academy of Sciences</i> , 1999 , 881, 81-91	6.5	70
424	Mourning and melancholia revisited: correspondences between principles of Freudian metapsychology and empirical findings in neuropsychiatry. <i>Annals of General Psychiatry</i> , 2008 , 7, 9	3.4	68
423	Randomised controlled study of sleep after nefazodone or paroxetine treatment in out-patients with depression. <i>British Journal of Psychiatry</i> , 2002 , 180, 528-35	5.4	68
422	A translational rodent assay of affective biases in depression and antidepressant therapy. <i>Neuropsychopharmacology</i> , 2013 , 38, 1625-35	8.7	67
421	A validation of the 7.5% CO ₂ model of GAD using paroxetine and lorazepam in healthy volunteers. <i>Journal of Psychopharmacology</i> , 2007 , 21, 42-9	4.6	67
420	Does the brain noradrenaline network mediate the effects of the CO ₂ challenge?. <i>Journal of Psychopharmacology</i> , 2003 , 17, 252-9	4.6	67
419	The effects of chronic ritanserin treatment on sleep and the neuroendocrine response to L-tryptophan. <i>Psychopharmacology</i> , 1987 , 93, 416-20	4.7	67
418	Inhibition of amine oxidase activity by derivatives that recognize imidazoline I ₂ sites. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 1995 , 272, 681-8	4.7	66
417	That warm fuzzy feeling: brain serotonergic neurons and the regulation of emotion. <i>Journal of Psychopharmacology</i> , 2009 , 23, 392-400	4.6	64
416	Significant decreases in frontal and temporal [¹¹ C]-raclopride binding after THC challenge. <i>NeuroImage</i> , 2010 , 52, 1521-7	7.9	63
415	LSD modulates music-induced imagery via changes in parahippocampal connectivity. <i>European Neuropsychopharmacology</i> , 2016 , 26, 1099-109	1.2	63
414	Neural correlates of the DMT experience assessed with multivariate EEG. <i>Scientific Reports</i> , 2019 , 9, 16324	4.9	63
413	DMT Models the Near-Death Experience. <i>Frontiers in Psychology</i> , 2018 , 9, 1424	3.4	62
412	L-Tryptophan and prolactin release: Evidence for interaction between 5-HT ₁ and 5-HT ₂ receptors. <i>Human Psychopharmacology</i> , 1986 , 1, 93-97	2.3	62
411	Microdosing psychedelics: More questions than answers? An overview and suggestions for future research. <i>Journal of Psychopharmacology</i> , 2019 , 33, 1039-1057	4.6	60
410	A proposal for an updated neuropsychopharmacological nomenclature. <i>European Neuropsychopharmacology</i> , 2014 , 24, 1005-14	1.2	60
409	Abstinence symptoms after withdrawal of tranquillising drugs: is there a common neurochemical mechanism?. <i>Lancet, The</i> , 1982 , 2, 360-2	4.0	60

408	Increased amygdala responses to emotional faces after psilocybin for treatment-resistant depression. <i>Neuropharmacology</i> , 2018 , 142, 263-269	5.5	59
407	Microbial infections in eight genomic subtypes of chronic fatigue syndrome/myalgic encephalomyelitis. <i>Journal of Clinical Pathology</i> , 2010 , 63, 156-64	3.9	59
406	Brain opioid receptor binding in early abstinence from alcohol dependence and relationship to craving: an [¹¹ C]diprenorphine PET study. <i>European Neuropsychopharmacology</i> , 2009 , 19, 740-8	1.2	58
405	Brain opioid receptor binding in early abstinence from opioid dependence: positron emission tomography study. <i>British Journal of Psychiatry</i> , 2007 , 191, 63-9	5.4	58
404	Generalized anxiety disorder: A comorbid disease. <i>European Neuropsychopharmacology</i> , 2006 , 16 Suppl 2, S109-18	1.2	58
403	Using [¹¹ C]diprenorphine to image opioid receptor occupancy by methadone in opioid addiction: clinical and preclinical studies. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2005 , 312, 309-15	4.7	57
402	A Lifetime Prevalence of Comorbidity Between Bipolar Affective Disorder and Anxiety Disorders: A Meta-analysis of 52 Interview-based Studies of Psychiatric Population. <i>EBioMedicine</i> , 2015 , 2, 1405-19	8.8	56
401	The use of benzodiazepines in anxiety and other disorders. <i>European Neuropsychopharmacology</i> , 1999 , 9 Suppl 6, S407-12	1.2	54
400	Dynamical exploration of the repertoire of brain networks at rest is modulated by psilocybin. <i>NeuroImage</i> , 2019 , 199, 127-142	7.9	53
399	In vivo imaging of microglial activation by positron emission tomography with [(11)C]PBR28 in the 5XFAD model of Alzheimer's disease. <i>Glia</i> , 2016 , 64, 993-1006	9	53
398	The role of the opioid system in alcohol dependence. <i>Journal of Psychopharmacology</i> , 2014 , 28, 8-22	4.6	53
397	Drug research: a plan for mental illness. <i>Nature</i> , 2012 , 483, 269	50.4	53
396	Substitution therapy for alcoholism: time for a reappraisal?. <i>Journal of Psychopharmacology</i> , 2012 , 26, 205-12	4.6	53
395	Brain dopamine response in human opioid addiction. <i>British Journal of Psychiatry</i> , 2008 , 193, 65-72	5.4	53
394	The role of dopamine and norepinephrine in depression and antidepressant treatment. <i>Journal of Clinical Psychiatry</i> , 2006 , 67 Suppl 6, 3-8	4.6	53
393	Doing it by numbers: a simple approach to reducing the harms of alcohol. <i>Journal of Psychopharmacology</i> , 2014 , 28, 3-7	4.6	52
392	Saccadic eye movement parameters in normal subjects. <i>Electroencephalography and Clinical Neurophysiology</i> , 1993 , 86, 69-74		52
391	Polymorphism of the 5-HT transporter and response to antidepressants: randomised controlled trial. <i>British Journal of Psychiatry</i> , 2011 , 198, 464-71	5.4	51

390	Serotonin transporter promoter region polymorphisms do not influence treatment response to escitalopram in patients with major depression. <i>European Neuropsychopharmacology</i> , 2009 , 19, 451-6	1.2	51
389	In vitro and ex vivo distribution of [3H]harmaline, an endogenous beta-carboline, in rat brain. <i>Neuropharmacology</i> , 2006 , 50, 269-76	5.5	51
388	Death and dependence: current controversies over the selective serotonin reuptake inhibitors. <i>Journal of Psychopharmacology</i> , 2003 , 17, 355-64	4.6	51
387	The effect of acutely administered MDMA on subjective and BOLD-fMRI responses to favourite and worst autobiographical memories. <i>International Journal of Neuropsychopharmacology</i> , 2014 , 17, 527-40	5.8	50
386	Effects of stressful life events, maternal depression and 5-HTTLPR genotype on emotional symptoms in pre-adolescent children. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2009 , 150B, 670-82	3.5	50
385	Mirtazapine: pharmacology in relation to adverse effects. <i>Acta Psychiatrica Scandinavica</i> , 1997 , 391, 31-76.5		50
384	The hidden third: improving outcome in treatment-resistant depression. <i>Journal of Psychopharmacology</i> , 2012 , 26, 587-602	4.6	49
383	History of cannabis use is not associated with alterations in striatal dopamine D2/D3 receptor availability. <i>Journal of Psychopharmacology</i> , 2012 , 26, 144-9	4.6	49
382	The Australian drug harms ranking study. <i>Journal of Psychopharmacology</i> , 2019 , 33, 759-768	4.6	48
381	In vivo imaging of cerebral dopamine D3 receptors in alcoholism. <i>Neuropsychopharmacology</i> , 2014 , 39, 1703-12	8.7	48
380	Effects of acute tyrosine/phenylalanine depletion on the selective processing of smoking-related cues and the relative value of cigarettes in smokers. <i>Psychopharmacology</i> , 2008 , 196, 611-21	4.7	48
379	Harms associated with psychoactive substances: findings of the UK National Drug Survey. <i>Journal of Psychopharmacology</i> , 2010 , 24, 147-53	4.6	47
378	Preliminary evidence of anxiolytic effects of the CRF(1) receptor antagonist R317573 in the 7.5% CO(2) proof-of-concept experimental model of human anxiety. <i>Journal of Psychopharmacology</i> , 2011 , 25, 1199-206	4.6	47
377	Noradrenergic mechanisms in the prefrontal cortex. <i>Journal of Psychopharmacology</i> , 1997 , 11, 163-8	4.6	47
376	The pharmacology of anxiety. <i>Current Topics in Behavioral Neurosciences</i> , 2010 , 2, 303-30	3.4	46
375	A translational, caffeine-induced model of onset insomnia in rats and healthy volunteers. <i>Psychopharmacology</i> , 2007 , 191, 943-50	4.7	46
374	Adverse effects from antidepressant treatment: randomised controlled trial of 601 depressed individuals. <i>Psychopharmacology</i> , 2014 , 231, 2921-31	4.7	45
373	[3H]2-(2-benzofuranyl)-2-imidazoline: a new selective high affinity radioligand for the study of rabbit brain imidazoline I2 receptors. <i>European Journal of Pharmacology</i> , 1996 , 304, 221-9	5.3	45

372	Generic legislation of new psychoactive drugs. <i>Journal of Psychopharmacology</i> , 2013 , 27, 317-24	4.6	44
371	The blind men and the elephant: Systematic review of systematic reviews of cannabis use related health harms. <i>European Neuropsychopharmacology</i> , 2020 , 33, 1-35	1.2	43
370	Voluntary exercise alters GABA(A) receptor subunit and glutamic acid decarboxylase-67 gene expression in the rat forebrain. <i>Journal of Psychopharmacology</i> , 2010 , 24, 745-56	4.6	43
369	Does alcohol increase the risk of overdose death: the need for a translational approach. <i>Addiction</i> , 2008 , 103, 1060-2	4.6	43
368	GABAA receptors: subtypes, regional distribution, and function. <i>Journal of Clinical Sleep Medicine</i> , 2006 , 2, S7-11	3.1	43
367	A Review of 3,4-methylenedioxymethamphetamine (MDMA)-Assisted Psychotherapy. <i>Frontiers in Psychiatry</i> , 2019 , 10, 138	5	42
366	GABA-benzodiazepine receptor function in alcohol dependence: a combined 11C-flumazenil PET and pharmacodynamic study. <i>Psychopharmacology</i> , 2005 , 180, 595-606	4.7	42
365	Biological markers of generalized anxiety disorder. <i>Dialogues in Clinical Neuroscience</i> , 2017 , 19, 147-158	5.7	42
364	Distinct Neuropsychological Mechanisms May Explain Delayed- Versus Rapid-Onset Antidepressant Efficacy. <i>Neuropsychopharmacology</i> , 2015 , 40, 2165-74	8.7	41
363	Depleting serotonin enhances both cardiovascular and psychological stress reactivity in recovered patients with anxiety disorders. <i>Journal of Clinical Psychopharmacology</i> , 2006 , 26, 414-8	1.7	41
362	Endogenous beta-carbolines as clonidine-displacing substances. <i>Annals of the New York Academy of Sciences</i> , 2003 , 1009, 157-66	6.5	41
361	Increased sympathetic response to standing in panic disorder. <i>Psychiatry Research</i> , 2003 , 118, 69-79	9.9	41
360	Benzodiazepine site pharmacokinetic/pharmacodynamic quantification in man: direct measurement of drug occupancy and effects on the human brain in vivo. <i>Neuropharmacology</i> , 1996 , 35, 1483-91	5.5	41
359	The Current Status of Psychedelics in Psychiatry. <i>JAMA Psychiatry</i> , 2021 , 78, 121-122	14.5	41
358	Therapeutic effects of classic serotonergic psychedelics: A systematic review of modern-era clinical studies. <i>Acta Psychiatrica Scandinavica</i> , 2021 , 143, 101-118	6.5	41
357	Panic attacks and alcohol withdrawal: can subjects differentiate the symptoms?. <i>Biological Psychiatry</i> , 1988 , 24, 240-3	7.9	40
356	A [11C]Ro15 4513 PET study suggests that alcohol dependence in man is associated with reduced β benzodiazepine receptors in limbic regions. <i>Journal of Psychopharmacology</i> , 2012 , 26, 273-81	4.6	39
355	Behavioral, neuroendocrine and neurochemical effects of the imidazoline I2 receptor selective ligand BU224 in naive rats and rats exposed to the stress of the forced swim test. <i>Psychopharmacology</i> , 2003 , 167, 195-202	4.7	39

354	Imidazoline binding sites in Huntington's and Parkinson's disease putamen. <i>European Journal of Pharmacology</i> , 1996 , 301, R19-21	5.3	39
353	Evaluation of C-BU99008, a PET Ligand for the Imidazoline Binding Site in Human Brain. <i>Journal of Nuclear Medicine</i> , 2018 , 59, 1597-1602	8.9	38
352	Acute increases in synaptic GABA detectable in the living human brain: a [¹¹ C]Ro15-4513 PET study. <i>NeuroImage</i> , 2014 , 99, 158-65	7.9	37
351	User perceptions of the benefits and harms of hallucinogenic drug use: A web-based questionnaire study. <i>Journal of Substance Use</i> , 2010 , 15, 283-300	0.8	37
350	Identification of ligands selective for central I2-imidazoline binding sites. <i>Neurochemistry International</i> , 1997 , 30, 47-53	4.4	37
349	Therapeutic mechanisms of psilocybin: Changes in amygdala and prefrontal functional connectivity during emotional processing after psilocybin for treatment-resistant depression. <i>Journal of Psychopharmacology</i> , 2020 , 34, 167-180	4.6	36
348	Gender differences in brain serotonin transporter availability in panic disorder. <i>Journal of Psychopharmacology</i> , 2011 , 25, 952-9	4.6	36
347	Serotonin and sensitivity to trauma-related exposure in selective serotonin reuptake inhibitors-recovered posttraumatic stress disorder. <i>Biological Psychiatry</i> , 2009 , 66, 17-24	7.9	36
346	Inhibition of central monoamine oxidase by imidazoline2 site-selective ligands. <i>Annals of the New York Academy of Sciences</i> , 1999 , 881, 114-7	6.5	36
345	Imidazoline 2 binding sites reflecting astroglia pathology in Parkinson's disease: an in vivo ¹¹ C-BU99008 PET study. <i>Brain</i> , 2019 , 142, 3116-3128	11.2	35
344	Psilocybin with psychological support improves emotional face recognition in treatment-resistant depression. <i>Psychopharmacology</i> , 2018 , 235, 459-466	4.7	35
343	Evaluation of ¹¹ C-BU99008, a PET ligand for the imidazoline2 binding sites in rhesus brain. <i>Journal of Nuclear Medicine</i> , 2014 , 55, 838-44	8.9	35
342	A comparison of the effects of a subtype selective and non-selective benzodiazepine receptor agonist in two CO(2) models of experimental human anxiety. <i>Journal of Psychopharmacology</i> , 2009 , 23, 117-22	4.6	35
341	Harmine and harmalan are bioactive components of classical clonidine-displacing substance. <i>Biochemistry</i> , 2004 , 43, 16385-92	3.2	35
340	Addiction: the clinical interface. <i>British Journal of Pharmacology</i> , 2008 , 154, 397-405	8.6	34
339	Naloxone displacement at opioid receptor sites measured in vivo in the human brain. <i>European Journal of Pharmacology</i> , 2003 , 459, 217-9	5.3	34
338	The neurobiology of social phobia. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 1999 , 249 Suppl 1, S11-8	5.1	34
337	Evaluation and initial in vitro and ex vivo characterization of the potential positron emission tomography ligand, BU99008 (2-(4,5-dihydro-1H-imidazol-2-yl)-1-methyl-1H-indole), for the imidazoline binding site. <i>Synapse</i> , 2012 , 66, 542-51	2.4	33

336	Variation in binding affinity of the novel anxiolytic XBD173 for the 18 kDa translocator protein in human brain. <i>Synapse</i> , 2011 , 65, 257-9	2.4	33
335	The administration of psilocybin to healthy, hallucinogen-experienced volunteers in a mock-functional magnetic resonance imaging environment: a preliminary investigation of tolerability. <i>Journal of Psychopharmacology</i> , 2011 , 25, 1562-7	4.6	33
334	Strain differences in response to a benzodiazepine receptor inverse agonist (FG 7142) in mice. <i>Psychopharmacology</i> , 1988 , 94, 335-6	4.7	33
333	Alcohol: the drug. <i>British Medical Bulletin</i> , 1994 , 50, 5-17	5.4	32
332	E-cigarettes are less harmful than smoking. <i>Lancet, The</i> , 2016 , 387, 1160-2	4.0	32
331	Psychiatry's next top model: cause for a re-think on drug models of psychosis and other psychiatric disorders. <i>Journal of Psychopharmacology</i> , 2013 , 27, 771-8	4.6	31
330	Adult night terrors and paroxetine. <i>Lancet, The</i> , 1997 , 350, 185	4.0	31
329	The use of sleep measures to compare a new 5HT1A agonist with buspirone in humans. <i>Journal of Psychopharmacology</i> , 2005 , 19, 609-13	4.6	31
328	Sleep changes during long-term treatment of depression with fluvoxamine--a home-based study. <i>Psychopharmacology</i> , 2000 , 149, 360-5	4.7	31
327	Elevating endogenous GABA levels with GAT-1 blockade modulates evoked but not induced responses in human visual cortex. <i>Neuropsychopharmacology</i> , 2013 , 38, 1105-12	8.7	30
326	Validating the inhalation of 7.5% CO(2) in healthy volunteers as a human experimental medicine: a model of generalized anxiety disorder (GAD). <i>Journal of Psychopharmacology</i> , 2011 , 25, 1192-8	4.6	30
325	Potential novel anxiolytic drugs. <i>Current Pharmaceutical Design</i> , 2008 , 14, 3534-46	3.3	30
324	Antidepressants and the adolescent brain. <i>Journal of Psychopharmacology</i> , 2015 , 29, 545-55	4.6	29
323	A pilot study of the effectiveness of D-cycloserine during cue-exposure therapy in abstinent alcohol-dependent subjects. <i>Psychopharmacology</i> , 2011 , 216, 121-9	4.7	29
322	Identification of an imidazoline binding protein: creatine kinase and an imidazoline-2 binding site. <i>Brain Research</i> , 2009 , 1279, 21-8	3.7	29
321	Acute tryptophan depletion alters gastrointestinal and anxiety symptoms in irritable bowel syndrome. <i>American Journal of Gastroenterology</i> , 2006 , 101, 2582-7	0.7	29
320	LSD alters eyes-closed functional connectivity within the early visual cortex in a retinotopic fashion. <i>Human Brain Mapping</i> , 2016 , 37, 3031-40	5.9	29
319	A placebo-controlled investigation of synaesthesia-like experiences under LSD. <i>Neuropsychologia</i> , 2016 , 88, 28-34	3.2	29

318	A pilot controlled study of the effects of flumazenil in posttraumatic stress disorder. <i>Biological Psychiatry</i> , 1997 , 41, 988-90	7.9	28
317	Treatment of depression and concomitant anxiety. <i>European Neuropsychopharmacology</i> , 2000 , 10 Suppl 4, S433-7	1.2	28
316	Anti-oxidant vitamins and mental performance of the elderly 1999 , 14, 459-471		28
315	Antidepressant drug development: Focus on triple monoamine reuptake inhibition. <i>Journal of Psychopharmacology</i> , 2015 , 29, 526-44	4.6	27
314	Cerebral blood flow predicts differential neurotransmitter activity. <i>Scientific Reports</i> , 2018 , 8, 4074	4.9	27
313	Imaging endogenous opioid peptide release with [11C]carfentanil and [3H]diprenorphine: influence of agonist-induced internalization. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2014 , 34, 1604-12	7.3	27
312	Effects of 7.5% CO2 challenge in generalized anxiety disorder. <i>Journal of Psychopharmacology</i> , 2011 , 25, 43-51	4.6	27
311	Increased serum free tryptophan in patients with diarrhea-predominant irritable bowel syndrome. <i>Nutrition Research</i> , 2010 , 30, 678-88	4	27
310	Reduced thalamic grey matter volume in opioid dependence is influenced by degree of alcohol use: a voxel-based morphometry study. <i>Journal of Psychopharmacology</i> , 2008 , 22, 7-10	4.6	27
309	D-Cycloserine and performance under different states of anxiety in healthy volunteers. <i>Psychopharmacology</i> , 2007 , 193, 579-85	4.7	27
308	Psychedelic drugs-a new era in psychiatry??. <i>Dialogues in Clinical Neuroscience</i> , 2019 , 21, 139-147	5.7	27
307	Nalmefene Reduces Reward Anticipation in Alcohol Dependence: An Experimental Functional Magnetic Resonance Imaging Study. <i>Biological Psychiatry</i> , 2017 , 81, 941-948	7.9	26
306	CNS drug development in Europe--past progress and future challenges. <i>Neurobiology of Disease</i> , 2014 , 61, 6-20	7.5	26
305	Neuroimaging of serotonin system in anxiety disorders. <i>Current Pharmaceutical Design</i> , 2012 , 18, 5699-708	7.8	26
304	Low sensitivity of the positron emission tomography ligand [11C]diprenorphine to agonist opiates. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2007 , 322, 661-7	4.7	26
303	2-(4,5-dihydro-1H-imidazol-2-yl)indazole (indazim) derivatives as selective I(2) imidazoline receptor ligands. <i>European Journal of Pharmaceutical Sciences</i> , 2003 , 20, 201-8	5.1	26
302	Using sleep to evaluate comparative serotonergic effects of paroxetine and citalopram. <i>European Neuropsychopharmacology</i> , 2004 , 14, 367-72	1.2	26
301	The effects of clonidine on cardiovascular responses to standing in healthy volunteers. <i>Clinical Autonomic Research</i> , 1995 , 5, 171-7	4.3	26

300	International consensus statement on major depressive disorder. <i>Journal of Clinical Psychiatry</i> , 2010 , 71 Suppl E1, e08	4.6	26
299	Self-blinding citizen science to explore psychedelic microdosing. <i>ELife</i> , 2021 , 10,	8.9	26
298	GABA receptor availability is not altered in adults with autism spectrum disorder or in mouse models. <i>Science Translational Medicine</i> , 2018 , 10,	17.5	26
297	Differences between magnetoencephalographic (MEG) spectral profiles of drugs acting on GABA at synaptic and extrasynaptic sites: a study in healthy volunteers. <i>Neuropharmacology</i> , 2015 , 88, 155-63	5.5	25
296	Imaging imidazoline-12 binding sites in porcine brain using 11C-BU99008. <i>Journal of Nuclear Medicine</i> , 2013 , 54, 139-44	8.9	25
295	Imagery of craving in opiate addicts undergoing detoxification. <i>Drug and Alcohol Dependence</i> , 1997 , 48, 25-31	4.9	25
294	Venlafaxine occupation at the noradrenaline reuptake site: in-vivo determination in healthy volunteers. <i>Journal of Psychopharmacology</i> , 2001 , 15, 9-12	4.6	25
293	Anxiolytic Potential of Benzodiazepine Receptor Partial Agonists. <i>CNS Drugs</i> , 1994 , 1, 305-315	6.7	25
292	A point mutation in the ion conduction pore of AMPA receptor GRIA3 causes dramatically perturbed sleep patterns as well as intellectual disability. <i>Human Molecular Genetics</i> , 2017 , 26, 3869-3882	5.6	24
291	Whole-exome sequencing identifies a polymorphism in the BMP5 gene associated with SSRI treatment response in major depression. <i>Journal of Psychopharmacology</i> , 2013 , 27, 915-20	4.6	24
290	GABAergic control of novelty stress-responsive epigenetic and gene expression mechanisms in the rat dentate gyrus. <i>European Neuropsychopharmacology</i> , 2011 , 21, 316-24	1.2	24
289	Characterisation of the effects of caffeine on sleep in the rat: a potential model of sleep disruption. <i>Journal of Psychopharmacology</i> , 2009 , 23, 475-86	4.6	24
288	Characterisation of the contribution of the GABA-benzodiazepine α receptor subtype to [(11)C]Ro15-4513 PET images. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2012 , 32, 731-44	7.3	24
287	Mirtazapine induces REM sleep behavior disorder (RBD) in parkinsonism. <i>Neurology</i> , 2003 , 61, 1161; author reply 1161	6.5	24
286	Moclobemide in the treatment of social phobia. <i>International Clinical Psychopharmacology</i> , 1996 , 11 Suppl 3, 77-82	2.2	24
285	Illegal drugs laws: clearing a 50-year-old obstacle to research. <i>PLoS Biology</i> , 2015 , 13, e1002047	9.7	23
284	Naltrexone ameliorates functional network abnormalities in alcohol-dependent individuals. <i>Addiction Biology</i> , 2018 , 23, 425-436	4.6	23
283	Management of insomnia: treatments and mechanisms. <i>British Journal of Psychiatry</i> , 2007 , 191, 195-7	5.4	23

282	A new approach to formulating and appraising drug policy: A multi-criterion decision analysis applied to alcohol and cannabis regulation. <i>International Journal of Drug Policy</i> , 2018 , 56, 144-152	5.5	22
281	Significant reductions in human visual gamma frequency by the gaba reuptake inhibitor tiagabine revealed by robust peak frequency estimation. <i>Human Brain Mapping</i> , 2016 , 37, 3882-3896	5.9	22
280	LSD modulates effective connectivity and neural adaptation mechanisms in an auditory oddball paradigm. <i>Neuropharmacology</i> , 2018 , 142, 251-262	5.5	22
279	Evidence for GABA-A receptor dysregulation in gambling disorder: correlation with impulsivity. <i>Addiction Biology</i> , 2017 , 22, 1601-1609	4.6	21
278	Spectral signatures of serotonergic psychedelics and glutamatergic dissociatives. <i>NeuroImage</i> , 2019 , 200, 281-291	7.9	21
277	Alcohol Hangover: Underlying Biochemical, Inflammatory and Neurochemical Mechanisms. <i>Alcohol and Alcoholism</i> , 2019 , 54, 196-203	3.5	21
276	The Imperial College Cambridge Manchester (ICCAM) platform study: An experimental medicine platform for evaluating new drugs for relapse prevention in addiction. Part A: Study description. <i>Journal of Psychopharmacology</i> , 2015 , 29, 943-60	4.6	21
275	Attacks on antidepressants: signs of deep-seated stigma?. <i>Lancet Psychiatry</i> , 2014 , 1, 102-4	23.3	21
274	The effects of single dose anxiolytic medication on the CO2 models of anxiety: differentiation of subjective and objective measures. <i>Journal of Psychopharmacology</i> , 2010 , 24, 649-56	4.6	21
273	Effects on sleep stages and microarchitecture of caffeine and its combination with zolpidem or trazodone in healthy volunteers. <i>Journal of Psychopharmacology</i> , 2009 , 23, 487-94	4.6	21
272	The feasibility of abrupt methadone-buprenorphine transfer in British opiate addicts in an outpatient setting. <i>Addiction Biology</i> , 1997 , 2, 191-200	4.6	21
271	GABA-A receptors and the response to CO(2) inhalation - a translational trans-species model of anxiety?. <i>Pharmacology Biochemistry and Behavior</i> , 2008 , 90, 51-7	3.9	21
270	Establishing non-inferiority in treatment trials in psychiatry: guidelines from an Expert Consensus Meeting. <i>Journal of Psychopharmacology</i> , 2008 , 22, 409-16	4.6	21
269	Impulsivity in abstinent alcohol and polydrug dependence: a multidimensional approach. <i>Psychopharmacology</i> , 2016 , 233, 1487-99	4.7	21
268	Acute D3 Antagonist GSK598809 Selectively Enhances Neural Response During Monetary Reward Anticipation in Drug and Alcohol Dependence. <i>Neuropsychopharmacology</i> , 2017 , 42, 1049-1057	8.7	20
267	Deaths from "legal highs": a problem of definitions. <i>Lancet, The</i> , 2014 , 383, 952	4.0	20
266	Noradrenergic function in generalized anxiety disorder: impact of treatment with venlafaxine on the physiological and psychological responses to clonidine challenge. <i>Journal of Psychopharmacology</i> , 2011 , 25, 78-86	4.6	20
265	GENetic and clinical predictors of treatment response in depression: the GenPod randomised trial protocol. <i>Trials</i> , 2008 , 9, 29	2.8	20

264	Development and validation of the Generalized Anxiety Disorder Inventory (GADI). <i>Journal of Psychopharmacology</i> , 2007 , 21, 145-52	4.6	20
263	Imaging alcohol cue exposure in alcohol dependence using a PET 15O-H2O paradigm: results from a pilot study. <i>Addiction Biology</i> , 2006 , 11, 107-15	4.6	20
262	Sleep and daytime sleepiness the next day following single night-time dose of fluvoxamine, dothiepin and placebo in normal volunteers. <i>Journal of Psychopharmacology</i> , 2000 , 14, 378-86	4.6	20
261	Was it a vision or a waking dream?. <i>Frontiers in Psychology</i> , 2014 , 5, 255	3.4	20
260	Investigating expectation and reward in human opioid addiction with [(11) C]raclopride PET. <i>Addiction Biology</i> , 2014 , 19, 1032-40	4.6	19
259	Evaluation of an operant successive negative contrast task as a method to study affective state in rodents. <i>Behavioural Brain Research</i> , 2012 , 234, 155-60	3.4	19
258	Emotional symptoms in children: The effect of maternal depression, life events, and COMT genotype. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2009 , 150B, 209-18	3.5	19
257	Sleep and its disorders in translational medicine. <i>Journal of Psychopharmacology</i> , 2011 , 25, 1226-34	4.6	19
256	Altered Insula Connectivity under MDMA. <i>Neuropsychopharmacology</i> , 2017 , 42, 2152-2162	8.7	18
255	Semantic activation in LSD: evidence from picture naming. <i>Language, Cognition and Neuroscience</i> , 2016 , 31, 1320-1327	2.4	18
254	Severity of depression and response to antidepressants: GENPOD randomised controlled trial. <i>British Journal of Psychiatry</i> , 2012 , 200, 130-6	5.4	18
253	Anhedonia and chronic mild stress model in depression. <i>Psychopharmacology</i> , 1997 , 134, 333-6; discussion 371-7	4.7	18
252	Autoradiographical distribution of imidazoline binding sites in monoamine oxidase A deficient mice. <i>Journal of Neurochemistry</i> , 2006 , 96, 1551-9	6	18
251	The clinical use of buprenorphine in opiate addiction: evidence and practice. <i>Acta Neuropsychiatrica</i> , 2004 , 16, 246-74	3.9	18
250	Flumazenil challenge in social phobia. <i>Depression and Anxiety</i> , 2000 , 11, 27-30	8.4	18
249	Evaluation of [O-methyl-11C]RS-15385-197 as a positron emission tomography radioligand for central alpha2-adrenoceptors. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2000 , 27, 475-84	8.8	18
248	Psilocybin and MDMA reduce costly punishment in the Ultimatum Game. <i>Scientific Reports</i> , 2018 , 8, 82364.9	4.9	18
247	Differentiated effects of the multimodal antidepressant vortioxetine on sleep architecture: Part 1, a pharmacokinetic/pharmacodynamic comparison with paroxetine in healthy men. <i>Journal of Psychopharmacology</i> , 2015 , 29, 1085-91	4.6	17

246	GABA-A receptor differences in schizophrenia: a positron emission tomography study using [C]Ro154513. <i>Molecular Psychiatry</i> , 2021 , 26, 2616-2625	15.1	17
245	History of cigarette smoking is associated with higher limbic GABAA receptor availability. <i>NeuroImage</i> , 2013 , 69, 70-7	7.9	17
244	Effects of naltrexone are influenced by childhood adversity during negative emotional processing in addiction recovery. <i>Translational Psychiatry</i> , 2017 , 7, e1054	8.6	17
243	Influence of different cellular environments on [(3)H]DASB radioligand binding. <i>Synapse</i> , 2012 , 66, 1035-24	9.4	17
242	Opiate agonists and antagonists modulate taste perception in opiate-maintained and recently detoxified subjects. <i>Journal of Psychopharmacology</i> , 2013 , 27, 265-75	4.6	17
241	Anxiety--bridging the heart/mind divide. <i>Journal of Psychopharmacology</i> , 2010 , 24, 633-8	4.6	17
240	Effects of 7.5% CO(2) inhalation on allocation of spatial attention to facial cues of emotional expression. <i>Cognition and Emotion</i> , 2011 , 25, 626-38	2.3	17
239	Current and former ecstasy users report different sleep to matched controls: a web-based questionnaire study. <i>Journal of Psychopharmacology</i> , 2009 , 23, 249-57	4.6	17
238	Serotonin release measured in the human brain: a PET study with [C]CIMBI-36 and d-amphetamine challenge. <i>Neuropsychopharmacology</i> , 2020 , 45, 804-810	8.7	17
237	Evidence for serotonin function as a neurochemical difference between fear and anxiety disorders in humans?. <i>Journal of Psychopharmacology</i> , 2015 , 29, 1061-9	4.6	16
236	3-Methyl-methcathinone: Pharmacokinetic profile evaluation in pigs in relation to pharmacodynamics. <i>Journal of Psychopharmacology</i> , 2015 , 29, 734-43	4.6	16
235	Natural speech algorithm applied to baseline interview data can predict which patients will respond to psilocybin for treatment-resistant depression. <i>Journal of Affective Disorders</i> , 2018 , 230, 84-86	6.6	16
234	The Hamilton Depression Scale--accelerator or break on antidepressant drug discovery?. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2014 , 85, 119-20	5.5	16
233	Dopamine transporter binding in females with panic disorder may vary with clinical status. <i>Journal of Psychiatric Research</i> , 2010 , 44, 56-9	5.2	16
232	Biological predictors of pharmacological therapy in anxiety disorders. <i>Dialogues in Clinical Neuroscience</i> , 2015 , 17, 305-17	5.7	16
231	The psychobiology of posttraumatic stress disorder. <i>Journal of Clinical Psychiatry</i> , 2000 , 61 Suppl 5, 24-9; discussion 30-2	4.6	16
230	Validated Method for the Quantification of Baclofen in Human Plasma Using Solid-Phase Extraction and Liquid Chromatography-Tandem Mass Spectrometry. <i>Journal of Analytical Toxicology</i> , 2016 , 40, 117-23	2.9	15
229	Acute naltrexone does not remediate fronto-striatal disturbances in alcoholic and alcoholic polysubstance-dependent populations during a monetary incentive delay task. <i>Addiction Biology</i> , 2017 , 22, 1576-1589	4.6	15

228	Effects of acute tryptophan depletion in serotonin reuptake inhibitor-remitted patients with generalized anxiety disorder. <i>Psychopharmacology</i> , 2010 , 208, 223-32	4.7	15
227	Distribution of [(3)H]BU224, a selective imidazoline I(2) binding site ligand, in rat brain. <i>European Journal of Pharmacology</i> , 2002 , 450, 55-60	5.3	15
226	A pharmacodynamic study of the alpha 2-adrenergic receptor antagonist ethoxyidazoxan in healthy volunteers. <i>Clinical Pharmacology and Therapeutics</i> , 1994 , 56, 420-9	6.1	15
225	First study of safety and tolerability of 3,4-methylenedioxymethamphetamine-assisted psychotherapy in patients with alcohol use disorder. <i>Journal of Psychopharmacology</i> , 2021 , 35, 375-383	4.6	15
224	An effective hangover treatment: Friend or foe?. <i>Drug Science, Policy and Law</i> , 2017 , 3, 2050324517741088		14
223	Stratified medicine in psychiatry: a worrying example or new opportunity in the treatment of anxiety?. <i>Journal of Psychopharmacology</i> , 2013 , 27, 119-22	4.6	14
222	Tryptophan depletion does not modify response to CCK-4 challenge in patients with panic disorder after treatment with citalopram. <i>Psychopharmacology</i> , 2006 , 186, 107-12	4.7	14
221	NICE: The National Institute of Clinical Excellence -- or Eccentricity? Reflections on the Z-drugs as hypnotics. <i>Journal of Psychopharmacology</i> , 2005 , 19, 125-7	4.6	14
220	5-Isothiocyanato-2-benzofuranyl-2-imidazoline (BU99006) an irreversible imidazoline(2) binding site ligand: in vitro and in vivo characterisation in rat brain. <i>Neuropharmacology</i> , 2002 , 43, 75-83	5.5	14
219	Probes for imidazoline binding sites: synthesis and evaluation of a selective, irreversible I2 ligand. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2000 , 10, 605-7	2.9	14
218	Whole-genome expression analysis reveals genes associated with treatment response to escitalopram in major depression. <i>European Neuropsychopharmacology</i> , 2016 , 26, 1475-1483	1.2	14
217	Ranking the harm of non-medically used prescription opioids in the UK. <i>Regulatory Toxicology and Pharmacology</i> , 2015 , 73, 999-1004	3.4	13
216	First study of safety and tolerability of 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy in patients with alcohol use disorder: preliminary data on the first four participants. <i>BMJ Case Reports</i> , 2019 , 12,	0.9	13
215	Pharmacology should be at the centre of all preclinical and clinical studies on new psychoactive substances (recreational drugs). <i>Journal of Psychopharmacology</i> , 2014 , 28, 711-8	4.6	13
214	Tripping up addiction: the use of psychedelic drugs in the treatment of problematic drug and alcohol use. <i>Current Opinion in Behavioral Sciences</i> , 2017 , 13, 71-76	4	13
213	The ICCAM platform study: An experimental medicine platform for evaluating new drugs for relapse prevention in addiction. Part B: fMRI description. <i>Journal of Psychopharmacology</i> , 2017 , 31, 3-16	4.6	13
212	Optimising PET approaches to measuring 5-HT release in human brain. <i>Synapse</i> , 2015 , 69, 505-11	2.4	13
211	Perverse effects of the precautionary principle: how banning mephedrone has unexpected implications for pharmaceutical discovery. <i>Therapeutic Advances in Psychopharmacology</i> , 2011 , 1, 35-6	4.9	13

210	In vitro and in vivo effect of BU99006 (5-isothiocyanato-2-benzofuranyl-2-imidazoline) on I2 binding in relation to MAO: evidence for two distinct I2 binding sites. <i>Neuropharmacology</i> , 2007 , 52, 395-404	5.5	13
209	Acute and chronic idazoxan in normal volunteers: biochemical, physiological and psychological effects. <i>Journal of Psychopharmacology</i> , 1991 , 5, 396-403	4.6	13
208	DMT alters cortical travelling waves. <i>ELife</i> , 2020 , 9,	8.9	13
207	So near yet so far: why won't the UK prescribe medical cannabis?. <i>BMJ Open</i> , 2020 , 10, e038687	3	13
206	The entropic tongue: Disorganization of natural language under LSD. <i>Consciousness and Cognition</i> , 2021 , 87, 103070	2.6	13
205	The influence of different cellular environments on PET radioligand binding: an application to D2/3-dopamine receptor imaging. <i>Neuropharmacology</i> , 2014 , 85, 305-13	5.5	12
204	Equivalent effects of acute tryptophan depletion on REM sleep in ecstasy users and controls. <i>Psychopharmacology</i> , 2009 , 206, 187-96	4.7	12
203	Introduction. The neurobiology of drug addiction: new vistas. <i>Philosophical Transactions of the Royal Society B: Biological Sciences</i> , 2008 , 363, 3109-11	5.8	12
202	Using saccadic eye movements as objective measures of tolerance in methadone dependent individuals during the hydromorphone challenge test. <i>Addiction Biology</i> , 2003 , 8, 59-66	4.6	12
201	Adverse effects of psychedelics: From anecdotes and misinformation to systematic science.. <i>Journal of Psychopharmacology</i> , 2022 , 2698811211069100	4.6	12
200	Can pragmatic research, real-world data and digital technologies aid the development of psychedelic medicine?. <i>Journal of Psychopharmacology</i> , 2021 , 2698811211008567	4.6	12
199	Current controversies in medical cannabis: Recent developments in human clinical applications and potential therapeutics. <i>Neuropharmacology</i> , 2021 , 191, 108586	5.5	12
198	Behavioural tasks sensitive to acute abstinence and predictive of smoking cessation success: a systematic review and meta-analysis. <i>Addiction</i> , 2016 , 111, 2134-2144	4.6	12
197	Blunted endogenous opioid release following an oral dexamphetamine challenge in abstinent alcohol-dependent individuals. <i>Molecular Psychiatry</i> , 2020 , 25, 1749-1758	15.1	12
196	Manifesto for an international digital mental health network 2019 , 2, 14-24		11
195	Medical cannabis in the UK: From principle to practice. <i>Journal of Psychopharmacology</i> , 2020 , 34, 931-937	4.6	11
194	Mind-altering drugs and research: from presumptive prejudice to a Neuroscientific Enlightenment?: Science & Society series on "Drugs and Science". <i>EMBO Reports</i> , 2014 , 15, 208-11	6.5	11
193	Elucidation of neurobiology of anxiety disorders in children through pharmacological challenge tests and cortisol measurements: a systematic review. <i>Journal of Psychopharmacology</i> , 2012 , 26, 431-42	4.6	11

192	Neuroscience in recession?. <i>Nature Reviews Neuroscience</i> , 2011 , 12, 297-302	13.5	11
191	The effects of 7.5% carbon dioxide inhalation on task performance in healthy volunteers. <i>Journal of Psychopharmacology</i> , 2012 , 26, 487-96	4.6	11
190	Popular intoxicants: what lessons can be learned from the last 40 years of alcohol and cannabis regulation?. <i>Journal of Psychopharmacology</i> , 2012 , 26, 213-20	4.6	11
189	Government vs science over drug and alcohol policy. <i>Lancet, The</i> , 2009 , 374, 1731-3	4.0	11
188	Characterization of [(3)H]harmaline binding to rat whole brain membranes. <i>Annals of the New York Academy of Sciences</i> , 2003 , 1009, 175-9	6.5	11
187	Assessment of GABA(A)benzodiazepine receptor (GBzR) sensitivity in patients on benzodiazepines. <i>Psychopharmacology</i> , 1999 , 146, 180-4	4.7	11
186	A comparison of the effects of phenelzine treatment with moclobemide treatment on cardiovascular reflexes. <i>International Clinical Psychopharmacology</i> , 1995 , 10, 229-38	2.2	11
185	Astrocyte reactivity with late-onset cognitive impairment assessed in vivo using C-BU99008 PET and its relationship with amyloid load. <i>Molecular Psychiatry</i> , 2021 ,	15.1	11
184	Inverse agonists - What do they mean for psychiatry?. <i>European Neuropsychopharmacology</i> , 2017 , 27, 87-90	1.2	10
183	Allowing for non-adherence to treatment in a randomized controlled trial of two antidepressants (citalopram versus reboxetine): an example from the GENPOD trial. <i>Psychological Medicine</i> , 2014 , 44, 2855-66	6.9	10
182	Evaluation of the effects of venlafaxine and pregabalin on the carbon dioxide inhalation models of Generalised Anxiety Disorder and panic. <i>Journal of Psychopharmacology</i> , 2013 , 27, 135-45	4.6	10
181	Changes in cardiovascular function after venlafaxine but not pregabalin in healthy volunteers: a double-blind, placebo-controlled study of orthostatic challenge, blood pressure and heart rate. <i>Human Psychopharmacology</i> , 2013 , 28, 562-75	2.3	10
180	The physical health challenges in patients with severe mental illness: cardiovascular and metabolic risks. <i>Journal of Psychopharmacology</i> , 2010 , 24, 1-8	4.6	10
179	What one hand giveth the other taketh away: some unpredicted effects of enantiomers in psychopharmacology. <i>Journal of Psychopharmacology</i> , 2010 , 24, 1137-41	4.6	10
178	Redistribution of slow wave activity of sleep during pharmacological treatment of depression with paroxetine but not with nefazodone. <i>Journal of Sleep Research</i> , 2009 , 18, 342-8	5.8	10
177	Alcohol alternatives--a goal for psychopharmacology?. <i>Journal of Psychopharmacology</i> , 2006 , 20, 318-20	4.6	10
176	A Delphi-method-based consensus guideline for definition of treatment-resistant depression for clinical trials.. <i>Molecular Psychiatry</i> , 2021 ,	15.1	10
175	Acute Tryptophan Depletion. Part I: Rationale and Methodology		10

174	Rationale for, barriers to, and appropriate medication for the long-term treatment of depression. <i>Journal of Clinical Psychiatry</i> , 2010 , 71 Suppl E1, e02	4.6	10
173	Lamotrigine for attention deficit-hyperactivity disorder comorbid with mood disorders: a case series. <i>Journal of Psychopharmacology</i> , 2014 , 28, 282-3	4.6	9
172	Where now for schizophrenia research?. <i>European Neuropsychopharmacology</i> , 2014 , 24, 1181-7	1.2	9
171	Resting state synchrony in anxiety-related circuits of abstinent alcohol-dependent patients. <i>American Journal of Drug and Alcohol Abuse</i> , 2013 , 39, 433-40	3.7	9
170	A U-shaped relationship between systolic blood pressure and panic symptoms: the HUNT study. <i>Psychological Medicine</i> , 2012 , 42, 1969-76	6.9	9
169	The Neurochemistry of Addiction. <i>Human Psychopharmacology</i> , 1997 , 12, S53-S58	2.3	9
168	The effects of electroconvulsive therapy on plasma insulin and glucose in depression. <i>British Journal of Psychiatry</i> , 1992 , 161, 94-8	5.4	9
167	Highlights of the international consensus statement on major depressive disorder. <i>Journal of Clinical Psychiatry</i> , 2011 , 72, e21	4.6	9
166	Effects of external stimulation on psychedelic state neurodynamics		9
165	Gamma-aminobutyric acid as a metabolite: Interpreting magnetic resonance spectroscopy experiments. <i>Journal of Psychopharmacology</i> , 2016 , 30, 422-7	4.6	9
164	Consensus statement and research needs: the role of dopamine and norepinephrine in depression and antidepressant treatment. <i>Journal of Clinical Psychiatry</i> , 2006 , 67 Suppl 6, 46-9	4.6	9
163	Increased global integration in the brain after psilocybin therapy for depression.. <i>Nature Medicine</i> , 2022 ,	50.5	9
162	Why medical cannabis is still out of patients' reach-an essay by David Nutt. <i>BMJ, The</i> , 2019 , 365, l1903	5.9	8
161	Psychopharmacological characterisation of the successive negative contrast effect in rats. <i>Psychopharmacology</i> , 2015 , 232, 2697-709	4.7	8
160	Influence of agonist induced internalization on [3H]Ro15-4513 binding-an application to imaging fluctuations in endogenous GABA with positron emission tomography. <i>Synapse</i> , 2015 , 69, 60-5	2.4	8
159	Harmane: an atypical neurotransmitter?. <i>Neuroscience Letters</i> , 2015 , 590, 1-5	3.3	8
158	The effect of a clinically effective and non-effective dose of lorazepam on 7.5% CO ₂ induced anxiety. <i>Human Psychopharmacology</i> , 2012 , 27, 540-8	2.3	8
157	Personalized risk assessment of drug-related harm is associated with health outcomes. <i>PLoS ONE</i> , 2013 , 8, e79754	3.7	8

156	Seizures in a night club. <i>Lancet, The</i> , 2007 , 370, 220	4.0	8
155	Alcohol and the Brain. <i>Nutrients</i> , 2021 , 13,	6.7	8
154	First evaluation of PET-based human biodistribution and radiation dosimetry of C-BU99008, a tracer for imaging the imidazoline binding site. <i>EJNMMI Research</i> , 2018 , 8, 71	3.6	8
153	Management of patients with depression associated with anxiety symptoms. <i>Journal of Clinical Psychiatry</i> , 1997 , 58 Suppl 8, 11-6	4.6	8
152	Care of depressed patients with anxiety symptoms. <i>Journal of Clinical Psychiatry</i> , 1999 , 60 Suppl 17, 23-7; discussion 46-8	4.6	8
151	Effect of short-term escitalopram treatment on neural activation during emotional processing. <i>Journal of Psychopharmacology</i> , 2016 , 30, 33-9	4.6	7
150	New victims of current drug laws. <i>Nature Reviews Neuroscience</i> , 2013 , 14, 877	13.5	7
149	Women with diarrhoea-predominant irritable bowel syndrome show an increased pressure response to 35% carbon dioxide stress challenge. <i>Stress</i> , 2009 , 12, 30-6	3	7
148	2-(4,5-Dihydroimidazol-2-yl)benzimidazoles as highly selective imidazoline I2/adrenergic alpha2 receptor ligands. <i>Bioorganic and Medicinal Chemistry</i> , 2006 , 14, 6679-85	3.4	7
147	The effects of the α -adrenoceptor antagonist idazoxan on sleep in normal volunteers. <i>Journal of Psychopharmacology</i> , 1991 , 5, 105-10	4.6	7
146	Are 5-HT receptors or beta-adrenoceptors involved in idazoxan-induced food and water intake?. <i>Neuropharmacology</i> , 1992 , 31, 1081-7	5.5	7
145	New psychoactive substances: Pharmacology influencing UK practice, policy and the law. <i>British Journal of Clinical Pharmacology</i> , 2020 , 86, 445-451	3.8	7
144	Using [(11C)Ro15 4513 PET to characterise GABA-benzodiazepine receptors in opiate addiction: Similarities and differences with alcoholism. <i>NeuroImage</i> , 2016 , 132, 1-7	7.9	7
143	Therapeutic Alliance and Rapport Modulate Responses to Psilocybin Assisted Therapy for Depression.. <i>Frontiers in Pharmacology</i> , 2021 , 12, 788155	5.6	7
142	Why Less Is Always More in the Treatment of Alcohol Use Disorders. <i>JAMA Psychiatry</i> , 2019 , 76, 359-360	14.5	6
141	Progress in mind: focus on alcohol use disorders, an elsevier resource centre. <i>Psychiatry Research</i> , 2015 , 226, 513-4	9.9	6
140	Cannabis and opioid overdoses: time to move on and examine potential mechanisms. <i>Addiction</i> , 2018 , 113, 1551-1552	4.6	6
139	The effect of 6-week treatment with escitalopram on CCK-4 challenge: a placebo-controlled study in CCK-4-sensitive healthy volunteers. <i>European Neuropsychopharmacology</i> , 2013 , 23, 645-52	1.2	6

138	Rapid tryptophan depletion following cognitive behavioural therapy for panic disorder. <i>Psychopharmacology</i> , 2011 , 213, 593-602	4.7	6
137	Is the association of hypertension and panic disorder explained by clustering of autonomic panic symptoms in hypertensive patients?. <i>Journal of Affective Disorders</i> , 2008 , 111, 344-50	6.6	6
136	Chapter 5.1 Phenomenology of anxiety disorders. <i>Handbook of Behavioral Neuroscience</i> , 2008 , 365-393	0.7	6
135	Assessment of GABAA benzodiazepine receptor (GBzR) sensitivity in patients with alcohol dependence. <i>Alcohol and Alcoholism</i> , 2008 , 43, 614-8	3.5	6
134	Relationship between imidazoline(2) sites and monoamine oxidase. <i>Annals of the New York Academy of Sciences</i> , 2003 , 1009, 353-6	6.5	6
133	Flumazenil and saccadic eye movements in patients with panic disorder and normal controls. <i>Human Psychopharmacology</i> , 1992 , 7, 45-50	2.3	6
132	Antidepressants and mania: To stop or not to stop?. <i>Human Psychopharmacology</i> , 1993 , 8, 357-360	2.3	6
131	Evidence that imipramine-induced postural hypotension may be centrally mediated. <i>Human Psychopharmacology</i> , 1988 , 3, 181-190	2.3	6
130	Acute Tryptophan Depletion. Part II: Clinical Effects and Implications		6
129	Developing a real-world evidence base for prescribed cannabis in the United Kingdom: preliminary findings from Project Twenty21. <i>Psychopharmacology</i> , 2021 , 1	4.7	6
128	Acute effects of MDMA on trust, cooperative behaviour and empathy: A double-blind, placebo-controlled experiment. <i>Journal of Psychopharmacology</i> , 2021 , 35, 547-555	4.6	6
127	Using Baclofen to Explore GABA-B Receptor Function in Alcohol Dependence: Insights From Pharmacokinetic and Pharmacodynamic Measures. <i>Frontiers in Psychiatry</i> , 2018 , 9, 664	5	6
126	Toxicological evaluation of 5-methoxy-2-aminoindane (MEAI): Binge mitigating agent in development. <i>Toxicology and Applied Pharmacology</i> , 2017 , 319, 59-68	4.6	5
125	Concerns regarding conclusions made about LSD-treatments (received 25 October 2016). <i>History of Psychiatry</i> , 2017 , 28, 257-260	0.6	5
124	Acute effects of cannabis on speech illusions and psychotic-like symptoms: two studies testing the moderating effects of cannabidiol and adolescence. <i>Psychological Medicine</i> , 2020 , 1-9	6.9	5
123	Disturbances across whole brain networks during reward anticipation in an abstinent addiction population. <i>NeuroImage: Clinical</i> , 2020 , 27, 102297	5.3	5
122	Let not the best be the enemy of the good. <i>Addiction</i> , 2011 , 106, 1892-3; discussion 1896-8	4.6	5
121	Does baseline fatigue influence treatment response to reboxetine or citalopram in depression? An open label randomized controlled trial. <i>Journal of Psychopharmacology</i> , 2012 , 26, 663-9	4.6	5

120	New directions in the treatment of anxiety disorders. <i>Expert Opinion on Therapeutic Patents</i> , 2003 , 13, 401-423	6.8	5
119	Identification of an I(2) binding protein from rabbit brain. <i>Annals of the New York Academy of Sciences</i> , 2003 , 1009, 364-6	6.5	5
118	In vivo estimation of imidazoline(2) binding site turnover. <i>Annals of the New York Academy of Sciences</i> , 2003 , 1009, 367-70	6.5	5
117	A Case Study of the 35% CO2 Challenge		5
116	Comparison of crude methanolic CDS extracts from various tissues. <i>Annals of the New York Academy of Sciences</i> , 1999 , 881, 92-6	6.5	5
115	Why doctors have a moral imperative to prescribe and support medical cannabis – an essay by David Nutt. <i>BMJ, The</i> , n3114	5.9	5
114	Study Protocol for "Psilocybin as a Treatment for Anorexia Nervosa: A Pilot Study". <i>Frontiers in Psychiatry</i> , 2021 , 12, 735523	5	5
113	Naltrexone differentially modulates the neural correlates of motor impulse control in abstinent alcohol-dependent and polysubstance-dependent individuals. <i>European Journal of Neuroscience</i> , 2019 , 50, 2311-2321	3.5	5
112	Addiction: lifestyle choice or medical diagnosis?. <i>Journal of Evaluation in Clinical Practice</i> , 2013 , 19, 493-62.5		4
111	A randomised trial of the effect of the glycine reuptake inhibitor Org 25935 on cognitive performance in healthy male volunteers. <i>Human Psychopharmacology</i> , 2014 , 29, 163-71	2.3	4
110	Effects of 7.5% CO2-Induced Anxiety on Individual Performance During a Group Computer Combat Game. <i>Military Psychology</i> , 2013 , 25, 615-622	0.9	4
109	Science and non-science in UK drug policy. <i>Addiction</i> , 2010 , 105, 1154	4.6	4
108	Antagonist-agonist combinations as therapies for heroin addiction: back to the future?. <i>Journal of Psychopharmacology</i> , 2010 , 24, 141-5	4.6	4
107	Psychopharmacology of benzodiazepines – an update. <i>Human Psychopharmacology</i> , 1995 , 10, S1-S14	2.3	4
106	Ketamine for the treatment of mental health and substance use disorders: comprehensive systematic review.. <i>BJPsych Open</i> , 2021 , 8, e19	5	4
105	Altered trajectories in the dynamical repertoire of functional network states under psilocybin		4
104	A multi criteria decision analysis (MCDA) for evaluating and appraising government policy responses to non medical heroin use. <i>International Journal of Drug Policy</i> , 2021 , 91, 103180	5.5	4
103	Compound asset sharing initiatives between pharmaceutical companies, funding bodies, and academia: Learnings and successes. <i>Pharmacology Research and Perspectives</i> , 2019 , 7, e00510	3.1	4

102	Imidazoline ligand BU224 reverses cognitive deficits, reduces microgliosis and enhances synaptic connectivity in a mouse model of Alzheimer's disease. <i>British Journal of Pharmacology</i> , 2021 , 178, 654-671	8.6	4
101	Imaging and Genetic Approaches to Inform Biomarkers for Anxiety Disorders, Obsessive-Compulsive Disorders, and PTSD. <i>Current Topics in Behavioral Neurosciences</i> , 2018 , 40, 219-292	3.4	4
100	Noradrenaline in depression: half a century of progress. <i>Journal of Psychopharmacology</i> , 1997 , 11, S3	4.6	4
99	Should the supply of cannabis be legalised now?. <i>BMJ, The</i> , 2019 , 366, l4473	5.9	3
98	Massive overuse or appropriate medical intervention? The modern-day use of antidepressants. <i>Current Opinion in Pharmacology</i> , 2012 , 12, 109-10	5.1	3
97	Reply to letter by Green, Marsden and Fone (2007) about Sessa and Nutt's editorial (MDMA: baby with the bath water) in the November 2007 journal. <i>Journal of Psychopharmacology</i> , 2008 , 22, 457-8	4.6	3
96	Pharmacological treatment of bipolar disorder. <i>Psychiatry (Abingdon, England)</i> , 2007 , 6, 305-308		3
95	Learning Perspectives on Anxiety Disorders	245-264	3
94	Panic Disorder: Clinical Course, Morbidity and Comorbidity	51-79	3
93	The Experience Sampling Method in Stress and Anxiety Research	289-306	3
92	Effects of LSD on music-evoked brain activity		3
91	A Multicriteria Decision Analysis Comparing Pharmacotherapy for Chronic Neuropathic Pain, Including Cannabinoids and Cannabis-Based Medical Products. <i>Cannabis and Cannabinoid Research</i> , 2021 ,	4.6	3
90	A pilot study of the effect of short-term escitalopram treatment on brain metabolites and gamma-oscillations in healthy subjects. <i>Journal of Psychopharmacology</i> , 2016 , 30, 579-80	4.6	3
89	Tapering of SSRI treatment to mitigate withdrawal symptoms. <i>Lancet Psychiatry, the</i> , 2019 , 6, 560-561	23.3	2
88	Considerations on the role of buprenorphine in recovery from heroin addiction from a UK perspective. <i>Journal of Psychopharmacology</i> , 2015 , 29, 43-9	4.6	2
87	Pharmacogenomics and Psychopharmacology	2020, 151-202	2
86	Don't panic. A guide to tryptophan depletion with disorder-specific anxiety provocation. <i>Journal of Psychopharmacology</i> , 2016 , 30, 1137-1140	4.6	2
85	Can Neuroscience Improve Addiction Treatment and Policies?. <i>Public Health Reviews</i> , 2013 , 35,	4.3	2

84	The role and basis of the drug laws. <i>Prometheus</i> , 2010 , 28, 293-297	0	2
83	UNDERSTANDING CAUSAL PATHWAYS: A RESPONSE TO THE COMMENTARIES. <i>Addiction</i> , 2008 , 103, 1067-1068	4.6	2
82	Tryptophan research in panic disorder. <i>International Journal of Tryptophan Research</i> , 2008 , 1, 3-12	5.6	2
81	The effect of 1-(4,5-dihydro-1H-imidazol-2-yl) isoquinoline on monoamine release and turnover in the rat frontal cortex. <i>Neuroscience Letters</i> , 2007 , 422, 109-113	3.3	2
80	Generalised Anxiety Disorder 187-204		2
79	The Pharmacology of Human Anxiety 309-324		2
78	Maintenance pharmacotherapy of unipolar depression. <i>Psychiatric Bulletin</i> , 1999 , 23, 370-373		2
77	Autoradiography of I2 receptors in frog brain. <i>Annals of the New York Academy of Sciences</i> , 1999 , 881, 208-11	6.5	2
76	Medical cannabis for severe treatment resistant epilepsy in children: a case-series of 10 patients. <i>BMJ Paediatrics Open</i> , 2021 , 5, e001234	2.4	2
75	Psychedelic experience dose-dependently modulated by cannabis: results of a prospective online survey. <i>Psychopharmacology</i> , 2021 , 1	4.7	2
74	Decreased brain modularity after psilocybin therapy for depression.		2
73	Pharmacological Treatment of Nocturnal Sleep Disturbances 53-66		2
72	Efficacy of mirtazapine in clinically relevant subgroups of depressed patients. <i>Depression and Anxiety</i> , 1998 , 7 Suppl 1, 7-10	8.4	2
71	New ACMD regulations threaten UK's pharmaceutical discovery. <i>Lancet, The</i> , 2017 , 389, 2283	4.0	1
70	The European College of Neuropsychopharmacology (ECNP) Medicines Chest Initiative: Rationale and Promise. <i>Pharmaceutical Medicine</i> , 2015 , 29, 269-273	2.3	1
69	Psychiatric Drug Discovery and Development 2020 , 35-68		1
68	Drugs to Treat Attention Deficit Hyperactivity Disorder (ADHD) 2020 , 392-432		1
67	P.6.f.002 Endogenous opioid release in pathological gamblers after an oral amphetamine challenge: a [¹¹ C]carfentanil PET study. <i>European Neuropsychopharmacology</i> , 2014 , 24, S699-S700	1.2	1

66	Recommended diagnosis and management of insomnia. <i>The Prescriber</i> , 2014 , 25, 12-20	0.4	1
65	Are multiple physical symptoms a poor prognostic factor or just a marker of depression severity? Secondary analysis of the GenPod trial. <i>Journal of Affective Disorders</i> , 2014 , 163, 40-6	6.6	1
64	Anxiolytics. <i>Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn</i> , 2012 , 106, 669-79	3	1
63	Brain Imaging in Addiction 2012 , 3-25		1
62	Nutt damage [Author's reply. <i>Lancet, The</i> , 2010 , 375, 724	4.0	1
61	Cardiac slowing and acute tryptophan depletion: a comment on the paper by van der Veen et al. <i>Psychopharmacology</i> , 2009 , 203, 831-3; author reply 835-6	4.7	1
60	Reply to OCD letter. <i>Journal of Psychopharmacology</i> , 2008 , 22, 338	4.6	1
59	Epidemiology of Anxiety Disorders1-23		1
58	Panic Disorder: Pathogenesis and Treatment81-103		1
57	Clinical Testing of Anxiolytic Drugs325-337		1
56	Paroxetine and its uses in psychiatry. <i>British Journal of Hospital Medicine</i> , 1999 , 60, 353-6		1
55	Opioids Neuroimaging 2013 , 675-687		1
54	Neural correlates of the DMT experience as assessed via multivariate EEG		1
53	The development and validation of a human screening model of tobacco abstinence. <i>Drug and Alcohol Dependence</i> , 2020 , 206, 107720	4.9	1
52	Some Contributions on How to Formulate Drug Policies and Provide Evidence-Based Regulation. <i>American Journal of Bioethics</i> , 2021 , 21, 28-31	1.1	1
51	Question-based Drug Development for psilocybin - Authors' reply. <i>Lancet Psychiatry,the</i> , 2016 , 3, 807	23.3	1
50	Chronic alcohol exposure differentially modulates structural and functional properties of amygdala: A cross-sectional study. <i>Addiction Biology</i> , 2021 , 26, e12980	4.6	1
49	Medical cannabis and epilepsy in the UK [A qualitative analysis of the carers' perspective: We're asking for quality of life for our children] <i>Drug Science, Policy and Law</i> , 2021 , 7, 205032452110349	1.8	1

48	Acute acetate administration increases endogenous opioid levels in the human brain: A [C]arfentanil molecular imaging study. <i>Journal of Psychopharmacology</i> , 2021 , 35, 606-610	4.6	1
47	Regulating the oxides of nitrogen [popping the myths. <i>Drug Science, Policy and Law</i> , 2022 , 8, 20503245221108521		
46	8. Neurobiologie des troubles anxieux 2014 , 69		o
45	Rob Kerwin--an appreciation. <i>Journal of Psychopharmacology</i> , 2007 , 21, 237	4.6	o
44	Functional evaluation of NK antagonism on cue reactivity in opiate dependence; An fMRI study. <i>Drug and Alcohol Dependence</i> , 2021 , 221, 108564	4.9	o
43	Putting the MD back into MDMA. <i>Nature Medicine</i> , 2021 , 27, 950-951	50.5	o
42	Sex differences in depressive symptoms and tolerability after treatment with selective serotonin reuptake inhibitor antidepressants: Secondary analyses of the GENPOD trial. <i>Journal of Psychopharmacology</i> , 2021 , 35, 919-927	4.6	o
41	Debunking the myth of 'Blue Mondays': No evidence of affect drop after taking clinical MDMA.. <i>Journal of Psychopharmacology</i> , 2021 , 2698811211055809	4.6	o
40	Effects of classic psychedelic drugs on turbulent signatures in brain dynamics. <i>Network Neuroscience</i> , 1-42	5.6	o
39	Individual and combined effects of cannabidiol and Δ^9 -tetrahydrocannabinol on striato-cortical connectivity in the human brain. <i>Journal of Psychopharmacology</i> , 2022 , 36, 732-744	4.6	o
38	A Brief History of Psychopharmacology 2020 , 1-34		
37	Neurotransmission and Mechanisms of Drug Action 2020 , 69-123		
36	Pharmacodynamics and Pharmacokinetics 2020 , 124-150		
35	Good Clinical Practice in Psychopharmacology 2020 , 203-203		
34	Drugs to Treat Depression 2020 , 227-267		
33	Drugs to Treat Anxiety and Insomnia 2020 , 268-289		
32	Drugs to Treat Schizophrenia and Psychosis (Dopamine Antagonists and Partial Agonists Other Than Clozapine) 2020 , 290-325		
31	Anticonvulsants for Mental Disorders: Valproate, Lamotrigine, Carbamazepine and Oxcarbazepine 2020 , 362-391		

- 30 Drugs to Treat Dementia **2020**, 433-453
- 29 Drugs to Treat Substance Use Disorders **2020**, 454-494
- 28 Electroconvulsive Therapy and Neuromodulation Therapies **2020**, 495-495
- 27 Psychotropic Drug Treatment in Childhood and Adolescence **2020**, 525-542
- 26 Psychotropic Drug Treatment in Later Life **2020**, 543-576
- 25 Psychotropic Prescribing in Pregnancy and Lactation **2020**, 577-598
- 24 The Clinical Management of Acute Disturbance Including Rapid Tranquillisation **2020**, 599-618
- 23 Antipsychotics, Weight Gain and Metabolic Risk **2020**, 619-619
- 22 A multicenter positron emission tomography study of GABA receptor availability in adults with autism. *European Neuropsychopharmacology*, **2017**, 27, S716-S717 1.2
- 21 Assessment of the quality of brain regions and neuroimaging metrics as biomarkers of Alzheimer's Disease. *EJNMMI Physics*, **2015**, 2, A46 4.4
- 20 Author's reply: Suppressing addiction using high-dose baclofen, rather than using substitution therapy *Journal of Psychopharmacology*, **2012**, 26, 1044-1044 4.6
- 19 Introducing the Pharmacology Behind Treatments to Understand Treatment Challenges. *European Psychiatry*, **2009**, 24, 1-1 6
- 18 Case History 3. *Human Psychopharmacology*, **1997**, 12, S39-S40 2.3
- 17 Drugs of Abuse John Q. Wang Humana Press. ISBN: 1-588-29057-3, 2003, 505 pp. with index, \$135.00. *Journal of Substance Use*, **2003**, 8, 279-279 0.8
- 16 Specific Phobias 105-135
- 15 Social Phobia 137-155
- 14 Post-Traumatic Syndromes: Comparative Biology and Psychology 205-221
- 13 Obsessive-Compulsive Disorder: Diagnostic Considerations and an Epidemiological Update 157-168

12 Genetics of Anxiety Disorders: Part I 25-40

11 Genetics of Anxiety Disorders: Part II 41-50

10 Obsessive-Compulsive Disorder: Biology and Treatment, a Generation of Progress 169-186

9 Current Trends in Cognitive Behaviour Therapy for Anxiety Disorders 265-286

8 Psychopharmacology: An Introduction (3rd edn). By René Spiegel. Chichester: John Wiley. 1996. 295 pp. £45 (hb). ISBN: 0 471 95729 1. *British Journal of Psychiatry*, **1997**, 170, 96-96 5-4

7 Practical pharmacotherapy for anxiety disorders. *Advances in Psychiatric Treatment*, **1997**, 3, 65-65

6 Functional Neuroimaging of the Acute Effects of Drugs of Abuse 83-104

5 How Current Drug Laws Impede Research and Clinical Treatments 206-214

4 A risky business? Comparing the harms of alcohol and other recreational drugs. *Significance*, **2021**, 18, 40-42 0.5

3 The psychopharmacology of anxiety. *British Journal of Hospital Medicine*, **1996**, 55, 187-91

2 The Psychobiology of Post-Traumatic Stress Disorder 223-244

1 The Tryptophan Depletion Technique in Psychiatric Research 359-369